Fluidigm Co. (NASDAQ:FLDM) CEO Stephen Christopher Linthwaite purchased 4,000 shares of the firm’s stock in a transaction that occurred on Friday, August 23rd. The stock was purchased at an average price of $5.52 per share, for a total transaction of $22,080.00. Following the acquisition, the chief executive officer now owns 171,391 shares of the company’s stock, valued at $946,078.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
FLDM traded down $0.18 during midday trading on Tuesday, reaching $5.15. 899,080 shares of the company were exchanged, compared to its average volume of 880,568. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.48 and a current ratio of 2.86. Fluidigm Co. has a one year low of $5.14 and a one year high of $14.90. The stock has a market capitalization of $371.98 million, a P/E ratio of -6.44 and a beta of 2.15. The stock’s 50-day simple moving average is $9.03 and its 200 day simple moving average is $11.50.
Fluidigm (NASDAQ:FLDM) last issued its earnings results on Thursday, August 1st. The medical research company reported ($0.20) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.08). Fluidigm had a negative return on equity of 31.45% and a negative net margin of 57.48%. The company had revenue of $28.20 million for the quarter, compared to the consensus estimate of $30.16 million. The business’s quarterly revenue was up 6.8% compared to the same quarter last year. On average, research analysts anticipate that Fluidigm Co. will post -0.55 earnings per share for the current year.
Several research firms recently issued reports on FLDM. ValuEngine cut Fluidigm from a “buy” rating to a “hold” rating in a report on Wednesday, June 12th. BidaskClub cut Fluidigm from a “hold” rating to a “sell” rating in a report on Friday, August 16th. Zacks Investment Research upgraded Fluidigm from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a report on Wednesday, July 3rd. Finally, Piper Jaffray Companies raised their price target on Fluidigm from $14.00 to $16.00 and gave the company an “overweight” rating in a report on Friday, May 3rd. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $14.75.
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow.
Read More: What is Liquidity?
Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.